BIOEMTECH technology makes possible what is considered impossible

As always, we are glad to see that BIOEMTECH’s technology makes possible what is considered impossible! Our collaborator at Radiomedix, Inc. are working on novel ²¹²Pb based radiopharmaceuticals for TAT of LDLR overexpressing solid tumors. We are happy that gamma-eye assisted the team to optimize the radiolabeling process and establish the preclinical imaging protocols.